Articles tagged with Prostate Cancer
A new study found that men diagnosed with prostate cancer have a higher risk of cardiovascular events and suicide, especially during the first year after diagnosis. The researchers attribute this to emotional stress associated with the diagnosis, which may lead to increased cardiovascular morbidity and suicidal thoughts.
Researchers Yoed Rabin and Kenji Shimada are developing an interactive simulator for cryosurgical procedures, combined with a computerized tutor to evaluate quality. This project aims to enhance surgical training by practicing virtual cryosurgical procedures, motivating surgeons to learn and improve their skills.
Researchers found that xanthohumol, a flavonoid derived from hops, blocks the effects of testosterone and prevents prostate cancer. The study suggests that this compound may have beneficial effects in animals, reducing hormone signaling and gene expression in prostate tissue.
Researchers found a strong inverse association between coffee consumption and the risk of lethal and advanced prostate cancers. Men who drank the most coffee had a 60% lower risk of aggressive prostate cancer.
Men with prostate cancer who engage in moderate exercise have improved overall survival, while vigorous exercise may decrease death rates from prostate cancer. Researchers found that three or more hours of physical activity per week lowered mortality risk by 35%.
A randomised trial found that medroxyprogesterone acetate is significantly more effective than venlafaxine at reducing hot flushes in men treated with androgen suppression therapy. Cyproterone acetate was also effective, but medroxyprogesterone is recommended as the standard treatment due to its fewer side effects.
A Mayo Clinic study found that routine annual evaluation of prostate growth is not a reliable predictor for prostate cancer development. However, if PSA levels are rising quickly, a prostate biopsy is recommended to determine if prostate cancer exists.
Researchers found that parathyroid hormone can elevate PSA levels in healthy men, leading to unnecessary biopsies and treatment. The study aims to refine the prostate cancer screening test to better differentiate between those who need a biopsy and those who may be spared.
Researchers at Yale University developed synthetic molecules that enhance the body's immune response to HIV and prostate cancer cells. The molecules work by binding to antibodies and proteins on infected cells, triggering an immune response and preventing infection.
Men with prostate cancer who experience PSA rise within 18 months of radiotherapy are at higher risk of developing spread and dying from their disease. The time between treatment and PSA recurrence has been shown to be a significant predictor of cancer-specific mortality.
A new study by Henry Ford Hospital found that a patient's socioeconomic status has no effect on their outcome following curative radiation therapy for prostate cancer. The study analyzed data from 788 patients and found that all patients, regardless of race or income, had similar survival rates and biochemical control rates.
Research led by Ohio State University found that aggressive prostate cancers have small, irregular blood vessels, while slow-growing tumors have more normal-appearing vessels. This study suggests using tumor blood vessel architecture to guide therapy and potentially improve long-term survival for patients.
A study presented at the American Society for Radiation Oncology (ASTRO) found that hypofractionated radiation treatment is more effective in stopping cancer from growing in high-risk prostate cancer patients compared to standard radiation therapy. The new treatment also had no increased risk of negative side effects, making it a valua...
A new study found that a shorter, five-week course of hypofractionated radiation is as effective as standard radiation therapy in reducing prostate cancer recurrence. The treatment delivered higher doses of radiation in fewer sessions, resulting in no significant difference in cancer recurrence or side effects between the two groups.
Researchers found that men with lower cholesterol levels had a 59% lower risk of developing high-grade prostate cancers, which tend to grow and spread rapidly. The study suggests that targeting cholesterol metabolism may be one route to treating and preventing the disease.
A phase III study found that short-term hormone therapy given prior to and during intermediate dose radiation treatment significantly increases the chance of living longer (51 percent) compared to those who receive radiation alone. The benefit appeared to be greatest for men at medium-risk for disease failure.
A study found that adding proton therapy 'boost' to X-ray radiation therapy significantly reduces prostate cancer recurrences in low- and intermediate-risk patients. The high-dose treatment also proves safe with minimal side effects, benefiting these patients with conventional doses of radiation.
A phase III study found that short-term hormone therapy added to radiation treatment significantly increases survival in medium-risk prostate cancer patients by 51% compared to those receiving radiation alone. In contrast, low-risk patients showed no significant benefit from this combination.
A U-M study found that exposure to androgen hormone relocates pieces of chromosome near each other, setting the scene for gene fusion in prostate cancer. This finding may lead to new screening tools or prevention strategies.
Researchers have developed a highly sensitive PSA assay using nanotechnology, enabling early detection of prostate cancer recurrence and improving treatment outcomes. The new technology has the potential to redefine the PSA 'zero' level, allowing for earlier diagnosis and targeted therapies.
Researchers from Germany investigated a large study of 589 prostate cancer patients between 2000 and 2006 and found no link between XMRV infection and the disease. Despite previous reports suggesting a potential association, the study detected no evidence for XMRV in German prostate cancer patients.
Researchers at Princess Margaret Hospital map a high-risk group for aggressive, 'hidden' prostate cancer, utilizing magnetic resonance imaging (MRI) to reveal tumors on the top of the prostate. The study identifies men with elevated PSA levels who benefit from MRI-guided biopsies.
A Swiss study found that prostate cancer patients with lower incomes receive worse care and have a higher risk of dying from the disease. The research suggests that socioeconomic status plays a significant role in prostate cancer mortality, with poorer patients receiving less comprehensive treatment and more advanced stages at diagnosis.
A large study by Mayo Clinic researchers found that patients treated with radiotherapy after prostate cancer surgery experienced very few complications, contradicting concerns about toxicity and side effects. The study suggests that radiation treatment is an effective and safe option for patients with recurrent cancer.
Recent trials have shown small reductions in prostate cancer mortality, but the potential benefits must be balanced against increased diagnosis rates and treatment complications. Developing more effective decision support tools may improve discussions between men and their physicians about screening.
A survey found that men largely make decisions about prostate cancer screening based on conversations with clinicians, but these discussions often do not include information about the risks of testing. Statistical modeling suggests that benefits and harms of PSA screening vary with age and risk level, with higher-risk men having more p...
A study published in the British Journal of Cancer found that 60% of prostate cancer cases lack aggressive protein Hsp-27, allowing for careful monitoring instead of treatment. The research could lead to a blood test to distinguish between aggressive and non-aggressive forms of prostate cancer.
A new study from the University of Michigan Comprehensive Cancer Center suggests that genetic risk of prostate cancer can be reduced by rescuing critical immune system cells. In mice with a gene called lymphotoxin alpha, these cells come back and delay tumor formation, potentially slowing cancer growth and spread.
A new study found that hormone therapy for prostate cancer increases the risk of developing heart problems, including coronary heart disease and heart attacks. The study suggests that doctors should consider heart-related side effects when prescribing endocrine therapy and refer patients to a cardiologist before starting treatment.
A study found improved survival rates for men with localized prostate cancer diagnosed between 1992 and 2002 compared to earlier eras. The 10-year prostate cancer-specific mortality rate was 8.3% for well-differentiated tumors, lower than previous reports.
Studies found significant DNA damage in humans with minor zinc deficiency, highlighting the health implications of inadequate intake. Experts recommend multivitamins for elderly individuals to ensure adequate levels, as zinc is essential for antioxidant defense and DNA repair.
Researchers have confirmed a link between Trichomonas vaginalis and an increased risk of prostate cancer. The study found that men infected with T. vaginalis were more likely to develop extraprostatic prostate cancer and cancer that is likely to progress to bony metastases or prostate cancer-specific death.
A strong association has been found between Trichomonas vaginalis infection and advanced, lethal prostate cancer in men. The study, published on the Journal of the National Cancer Institute website, analyzed blood samples from 673 men with prostate cancer and compared infection status to 673 control subjects.
Researchers at Columbia University Irving Medical Center found a new type of adult stem cell, CARNs, in the prostate that can give rise to cancer if tumor suppressor genes are inactivated. The discovery resolves controversy over the origin of prostate cancer cells and may help develop better treatments.
A study has found that XMRV retrovirus is present in 27% of prostate cancers, associated with more aggressive tumors. The viral proteins were predominantly found in malignant prostatic cells, suggesting a direct link between XMRV infection and tumor formation.
A new study confirms associations between SNPs and increased prostate cancer risk in Japanese men, similar to findings in European populations. Men with six or more risk alleles had substantially higher risk for prostate cancer.
A new study published in The Journal of Nuclear Medicine shows that PET/CT scans with the imaging agent choline can detect recurring prostate cancer sooner than conventional imaging technologies. Researchers found a strong association between PET/CT detection and PSA levels, and suggest using specific criteria to reduce unnecessary scans.
Researchers estimated that 1.3 million extra cases were diagnosed and over a million treated since 1986 due to overdiagnosis of prostate cancer through PSA screening. The majority of these cases involve younger men.
A new study found that men diagnosed with low-risk prostate cancers who deferred treatment were still doing fine an average of eight years after their diagnosis. Only half of these men eventually underwent any treatment 10 to 15 years post-diagnosis, preserving their quality of life.
A recent study found that the racial disparity gap in prostate cancer stage at diagnosis has decreased over time. More men were diagnosed with prostate cancer at an earlier age and stage in 2004-2005 compared to earlier years, according to data from the Surveillance, Epidemiology, and End Results program.
Men with coronary artery disease-induced congestive heart failure or heart attack who receive hormone therapy before or along with radiation therapy for prostate cancer have a higher risk of death, according to a study. However, in men without comorbidities, hormone therapy was not associated with an increased risk of all-cause mortality.
A new study has found that high serum insulin levels are associated with an increased risk of prostate cancer, even within the normal range. Insulin-like growth factors may play a role in prostate cancer development.
Researchers at USC have identified novel genetic mechanisms that govern an individual's risk of developing prostate cancer, highlighting the role of gene 'deserts' and regulatory sequences. The study found that genetic variations in these regions can modulate gene expression, increasing the risk for certain diseases.
A new study has found that obesity increases the risk of prostate cancer recurrence in both black and white men, with no racial difference observed. Researchers analyzed data from 1,415 patients and found a significant association between higher body mass index and increased risk of cancer recurrence.
A new study found that denosumab significantly increased bone density at all monitored sites and reduced new vertebral fractures by 62% in men receiving androgen-deprivation therapy for prostate cancer. The treatment also showed improvements in bone density at the radius, one of the bones in the forearm.
Oral sodium clodronate reduces death by 23% and increases overall survival to 30% at 5 years for patients with advanced prostate cancer. However, in men with localized disease, clodronate shows no improvement in overall survival.
A new study by Louis Potters and colleagues found that permanent prostate brachytherapy is an effective treatment option for younger patients diagnosed with prostate cancer, with success rates comparable to older patients. The study analyzed data from 2,119 patients and showed that age didn't impact the long-term therapeutic outcome of...
A University of North Carolina study found that establishing a regular relationship with a healthcare provider reduces racial disparities in prostate cancer diagnosis. Men with ongoing relationships are more likely to receive screenings and less likely to be diagnosed with advanced disease.
The North Carolina-Louisiana Prostate Cancer Project finds differences in physician trust, access to care, and continuity of care between African American and Caucasian men, leading to advanced prostate cancer at diagnosis. An established relationship with a healthcare provider can mitigate these disparities.
Researchers have identified MEK4 as a key player in promoting cell invasion in prostate cancer. Genistein, a dietary compound, inhibits MEK4 kinase activity, suggesting potential therapeutic applications for prostate cancer treatment.
A recent study published in Cancer found that men with early stages of prostate cancer who delay radical treatment have acceptable levels of anxiety and distress. The study's results suggest that living with untreated cancer is not upsetting for many patients, but certain mental and physical factors can increase distress.
A large-scale study found that only 12% of men who underwent radical prostatectomy between 1987 and 2005 died from prostate cancer within 15 years. The low mortality rate suggests that some patients with slow-growing cancers may not need immediate treatment.
Researchers at Ohio State University Comprehensive Cancer Center and Dana-Farber Cancer Institute reveal how late-stage prostate tumors gain ability to grow without hormones. The study identifies a gene called UBE2C as key regulator in hormone-independent growth.
Developed a compact gamma camera called ProxiScan to localize prostate cancer tissue with high resolution. The camera system enables early diagnosis and treatment of potentially deadly disease.
Researchers have discovered a new gene fusion, NDRG1-ERG, that produces a protein potentially targeted by drug therapies. This finding may improve prostate cancer testing and treatment options.
Researchers found that finasteride use made no difference in high-grade cancer rates among men without cancer warning signs, but significantly reduced the risk in those with abnormal digital rectal exams or elevated PSA levels. The study suggests doctors can be less cautious in using finasteride for preventive treatment.
Dr. Nima Sharifi received a $375,000 grant to study genes that determine prostate cancer resistance to androgen deprivation therapy. The funding supports his laboratory's work in developing new therapies.
A new molecule finds and penetrates prostate cancer cells, allowing for targeted treatment and improved imaging. The targeting molecule has the potential to reduce toxic side effects and improve diagnosis of prostate cancer.
A new three-way measurement method has been developed to predict disease metastasis in prostate cancer, combining PSA doubling time, Gleason score, and interval between surgery and detectable PSA levels. This improved prediction method may help determine which patients benefit from additional therapy after surgery.
The July issue of European Urology reviews prostate cancer screening studies, highlighting the need to balance mortality reduction with overdiagnosis risks. The EAU adopts the conclusions of the ERSPC study and recognizes the benefit of screening for mortality reduction.